Clinical Trial Enrollments, Bond Offerings, Innovative Solutions, Leadership Appointments, and Certifications - Research Report on Baxter, Mylan, Becton Dickinson, Align and Allscripts

NEW YORK, November 27, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Mylan, Inc. (NASDAQ: MYL), Becton, Dickinson and Company (NYSE: BDX), Align Technology Inc. (NASDAQ: ALGN) and Allscripts Healthcare Solutions, Inc. (NASDAQ: MDRX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Baxter International Inc. Research Report

On November 13, 2013, Baxter International Inc. (Baxter) announced the completion of enrollment in its Phase III clinical trial of BAX 855 - an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. Baxter added that the ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates in both prophylaxis and on-demand treatment schedules, and evaluating its safety and pharmacokinetic profile. Anders Ullman, M.D., Ph.D., Vice President of Global Research and Development in Baxter's BioScience business, said, "The BAX 855 development program is a priority for Baxter as we evaluate the potential to provide an efficacious and safe treatment with an extended half-life for patients with hemophilia."The Company stated that based upon the results of the study, it expects to complete the trial and file for regulatory approval late in 2014. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=DDD

http://www.analystscorner.com/r/full_research_report/163d_BAX

--

Mylan, Inc Research Report

On November 19, 2013, Mylan Inc. (Mylan) announced the pricing of a registered offering amounting to an aggregate principal amount of $2.0 billion, as follows: 1.35% Senior Notes due 2016, 2.55% Senior Notes due 2019, 4.20% Senior Notes due 2023; and 5.40% Senior Notes due 2043.The Company reported that the aggregate principal amount of each of these aforesaid mentioned notes is $500 million. Mylan stated that it plans to use the offering's net proceeds to fund the previously announced acquisition of the Agila Specialties business of Strides Arcolab and for general corporate purposes. The Company expects the sale of the note to close on or about November 29, 2013, subject to customary closing conditions. The Full Research Report on Mylan, Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/5a20_MYL

--

Becton, Dickinson and Company Research Report

On November 19, 2013, BD Medical, a segment of Becton, Dickinson and Company, announced that the BD Accelerate^SMprogram now offers a solution for the biopharmaceutical injectable drug market with the BD Neopak™ Glass Prefillable Syringe system. The Company stated that the program is intended to facilitate expedited delivery, within two weeks, of fully-validated BD syringe systems and associated quality systems documentation to pharmaceutical customers. Eric Borin, Vice President and General Manager - Americas, BD Medical - Pharmaceutical Systems stated, "By offering faster access to a syringe system that is specifically engineered for the delivery of biopharmaceutical drugs, BD is positioned to provide an important advantage to companies developing these products to address a wide range of unmet healthcare needs. The availability of the BD Neopak™ Glass Prefillable Syringe system through the BD Accelerate^SMprogram demonstrates BD's understanding of its pharmaceutical partners' current challenges when bringing drugs to market for patients." The Full Research Report on Becton, Dickinson and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/0175_BDX

--

Align Technology Inc. Research Report

On November 18, 2013, Align Technology, Inc. (Align) announced that it has appointed Zelko Relic as the Company's Vice President of Research & Development, with effect from December 2, 2013. The Company stated that Relic in his new role will be responsible for the Company's global research and development initiatives, and will report directly to Align's President and CEO, Thomas M. Prescott. The Company informed that prior to joining Align, Mr. Relic served as the Vice President, engineering for Datalogic Automation. Thomas M. Prescott stated, "Product and technology innovation is one of our most important strategic growth drivers and I am pleased to have Zelko lead our efforts and teams worldwide. His extensive knowledge of software development and advanced technologies in the healthcare, semiconductor and automation industries adds a valuable range and depth of experience to our leadership team." The Full Research Report on Align Technology Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/69b3_ALGN

--

Allscripts Healthcare Solutions, Inc. Research Report

On November 15, 2013, Allscripts Healthcare Solutions, Inc. (Allscripts) announced that Allscripts dbMotion 5.0, its electronic health record (EHR) software, has been tested and certified under the Drummond Group's Electronic Health Records Office of the National Coordinator Authorized Certification Body (ONC-ACB) program. The Company informed that Drummond Group's ONC-ACB certification program certifies that EHRs meet the meaningful use criteria for either eligible provider or hospital technology. Paul M. Black, President and CEO of Allscripts stated, "Managing transitions of care is an essential component to Meaningful Use Stage 2. dbMotion serves as the digital key to unlock the open exchange of critical patient information across disparate systems. With this certification, providers can rest assured they are using a solution that will help them and their communities achieve Meaningful Use Stage 2 while enhancing patient care and lower costs." The Full Research Report on Allscripts Healthcare Solutions, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://analystscorner.com/microwriter/link.php?s=

http://www.analystscorner.com/r/full_research_report/1787_MDRX

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsCorner.com

SOURCE Analysts' Corner